WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules

WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in […]

Weiterlesen

WELDING GmbH & Co. KG se expande a Latinoamérica

WELDING GmbH & Co. KG anuncia la creación de su subsidiaria mexicana, WELDING Ingredientes SA de CV. Con este paso, nuestra empresa familiar amplía su presencia internacional y fortalece su […]

Weiterlesen